BioSpace News Archive

4D Molecular Therapeutics (Nasdaq: FDMT), a clinical-stage gene therapy company harnessing the power of directed evolution for targeted gene therapies, announced financial results for the second quarter of 2021, and provided operational highlights.

Nkarta, Inc., a biopharmaceutical company developing engineered natural killer cell therapies to treat cancer, reported financial results for the second quarter ended June 30, 2021.

Seer Inc. (NASDAQ: SEER), a life sciences company commercializing a disruptive new platform for proteomics, today announced it has signed an exclusive distribution agreement with Enlight Medical, a leading company in the development, production and distribution of innovative medical diagnostics and therapeutic devices in China.

NeuroPace, Inc., a commercial-stage medical device company focused on transforming the lives of people suffering from epilepsy, reported financial results for the quarter ended June 30, 2021.

NeuBase Therapeutics, Inc. (Nasdaq: NBSE) (“NeuBase” or the “Company”), a biotechnology platform company Drugging the Genome™ to address disease at the base level using a new class of precision genetic medicines, today reported its financial results for the three- and nine-month periods ended June 30, 2021.

Angion Biomedica Corp (NASDAQ:ANGN), a late-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel small molecule therapeutics to address acute organ injuries and fibrotic diseases, today provided a corporate update and reported financial results for the quarter ended June 30, 2021.

Helius Medical Technologies, Inc., a neurotech company focused on neurological wellness, reported financial results for the quarter ended June 30, 2021.

Adicet Bio, Inc., a biotechnology company discovering and developing first-in-class allogeneic gamma delta T cell therapies for cancer and other diseases, reported operational highlights and financial results for the second quarter ended June 30, 2021.

Sight Sciences, Inc., an eyecare technology company focused on creating innovative solutions intended to transform standards of care and improve patients’ lives, reported financial results for the quarter ended June 30, 2021.

CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet need, today announced corporate updates and financial results for the second quarter ended June 30, 2021.